A Phase 3 interventional study of Valsartan/hydrochlorothiazide (HCTZ) and Valsartan/amlodipine in Hypertension, sponsored by Novartis. Completed at 5 sites in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2010-09-27.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 123 studies testing hydrochlorothiazide in Hypertension — 2 open to participants now, 3 under way, none of them phase 3. Hydrochlorothiazide · Hypertension.
Among the 123 studies testing hydrochlorothiazide in Hypertension, this one is the 83rd largest by enrollment of the 121 interventional ones that give a count, is one of 8 that started in 2007, is one of 35 in phase 3, and was the 47th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →2 of the 123 studies testing hydrochlorothiazide in Hypertension are open now, in 2 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
By country, each count listing its studies:
Hydrochlorothiazide: first FDA approval 1959 (ESIDRIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
123 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 229 across the 121 interventional studies. Of the 108 that completed or were terminated, 35 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 123 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 159th largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2007, is one of 108 in phase 3, and was the 129th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
2 of the studies testing hydrochlorothiazide in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04676399University of Kansas Medical CenterImproving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction | 2026-12 |
| NCT07271420Chinese University of Hong KongBlood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 123 studies testing hydrochlorothiazide in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine potential pharmacokinetic drug-drug interaction when three drugs (valsartan, amlodipine, and hydrochlorothiazide) are co-administered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Drug: Valsartan/hydrochlorothiazide (HCTZ)
Drug: Valsartan/amlodipine
Drug: Amlodipine/hydrochlorothiazide(HCTZ)
Drug: Valsartan/amlodipine/hydrochlorothiazide(HCTZ)
Drug page: Hydrochlorothiazide
Drug pages: Valsartan · Amlodipine
Drug page: Hydrochlorothiazide
Drug page: Hydrochlorothiazide
Potential drug interaction and effect on blood level of drugs when co-administered for 17 days
Safety and tolerability of co-administered assessed by capturing adverse events and safety laboratory
The record gives a start of Sep 2007 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hydrochlorothiazide · Valsartan · Amlodipine